TORRENT PHARMACEUTICALS L
Latest filings
- Analyst call audio link posted for September 2026 results · Investor Communications
- Torrent Pharma approves September quarter and half-year results · Board & Shareholder Meetings
- Q2 FY27 revenue rises 51%, but consolidated net profit falls 10% · Results
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations including Semaglutide products sold under the Semalix brand (injection pens in 2mg, 4mg, and 8mg doses, plus oral tablets), some of which are sourced from third-party manufacturers such as Dr. Reddy's Laboratories and MSN Labs. The business operates across India, the US, and Brazil, and the merger of J.B. Chemicals & Pharmaceuticals into the company became effective on 8 July 2026 with an appointed date of 21 January 2026. In Q1 FY27, the India business grew 19% year-on-year, the US business 36%, and Brazil 27%. For FY26, employee expenses were 19.1% of revenue, other operating expenses 24.0%, raw materials 12.6%, and depreciation 8.0%. Capital expenditure ran at 4.8% of FY26 revenue.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from TORRENT PHARMACEUTICALS L's filed financials and exchange disclosures
What does TORRENT PHARMACEUTICALS L do?
TORRENT PHARMACEUTICALS L is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol TORNTPHARM.
Is TORRENT PHARMACEUTICALS L profitable?
Yes. Over the trailing twelve months TORRENT PHARMACEUTICALS L reported a net profit of ₹2,156 Cr on revenue of ₹15,723 Cr.
Does TORRENT PHARMACEUTICALS L pay a dividend?
Yes. The dividend yield is 0.83% at the current price. It paid out 60% of its profit as dividend in FY26.
Is TORRENT PHARMACEUTICALS L debt-free?
No. It reported borrowings of ₹14,798 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹13,681 Cr after cash. Debt stands at 0.84× equity. That is higher than 91% of its 166 Pharmaceuticals peers.
Is TORRENT PHARMACEUTICALS L expensive compared with its peers?
On trailing P/E, TORRENT PHARMACEUTICALS L ranks 132 of 158 in Pharmaceuticals — cheaper than 17% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the TORRENT PHARMACEUTICALS L share price move in a day?
On a typical session TORRENT PHARMACEUTICALS L moves 0.75% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track TORRENT PHARMACEUTICALS L's announcements?
Every NSE and BSE filing by TORRENT PHARMACEUTICALS L appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.